WO2004094637A1 - アレルゲン特異的t細胞抗原決定基を植物へ集積させる方法、および該抗原決定基を集積させた植物 - Google Patents
アレルゲン特異的t細胞抗原決定基を植物へ集積させる方法、および該抗原決定基を集積させた植物 Download PDFInfo
- Publication number
- WO2004094637A1 WO2004094637A1 PCT/JP2004/005938 JP2004005938W WO2004094637A1 WO 2004094637 A1 WO2004094637 A1 WO 2004094637A1 JP 2004005938 W JP2004005938 W JP 2004005938W WO 2004094637 A1 WO2004094637 A1 WO 2004094637A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plant
- cell
- dna
- allergen
- peptide
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 105
- 239000013566 allergen Substances 0.000 title claims description 87
- 239000000427 antigen Substances 0.000 title description 8
- 108091007433 antigens Proteins 0.000 title description 8
- 102000036639 antigens Human genes 0.000 title description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 172
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 162
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 87
- 235000009566 rice Nutrition 0.000 claims abstract description 87
- 230000031787 nutrient reservoir activity Effects 0.000 claims abstract description 58
- 241000218645 Cedrus Species 0.000 claims abstract description 21
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims abstract description 20
- 241000209094 Oryza Species 0.000 claims abstract 10
- 108020004414 DNA Proteins 0.000 claims description 114
- 241000196324 Embryophyta Species 0.000 claims description 114
- 210000004027 cell Anatomy 0.000 claims description 45
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 43
- 239000013598 vector Substances 0.000 claims description 38
- 208000026935 allergic disease Diseases 0.000 claims description 32
- 235000013305 food Nutrition 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 238000004873 anchoring Methods 0.000 claims description 14
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 14
- 239000013573 pollen allergen Substances 0.000 claims description 14
- 230000009261 transgenic effect Effects 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 230000003449 preventive effect Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 abstract description 33
- 206010048908 Seasonal allergy Diseases 0.000 abstract description 9
- 229940126576 edible vaccine Drugs 0.000 abstract description 2
- 201000004338 pollen allergy Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 97
- 240000007594 Oryza sativa Species 0.000 description 77
- 102000004169 proteins and genes Human genes 0.000 description 50
- 238000009825 accumulation Methods 0.000 description 37
- 230000014509 gene expression Effects 0.000 description 30
- 238000004458 analytical method Methods 0.000 description 21
- 206010020751 Hypersensitivity Diseases 0.000 description 18
- JBFQOLHAGBKPTP-NZATWWQASA-N (2s)-2-[[(2s)-4-carboxy-2-[[3-carboxy-2-[[(2s)-2,6-diaminohexanoyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)C(CC(O)=O)NC(=O)[C@@H](N)CCCCN JBFQOLHAGBKPTP-NZATWWQASA-N 0.000 description 14
- 108010089256 lysyl-aspartyl-glutamyl-leucine Proteins 0.000 description 14
- 230000007815 allergy Effects 0.000 description 13
- 230000005070 ripening Effects 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 238000010586 diagram Methods 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 108060006613 prolamin Proteins 0.000 description 9
- 230000006058 immune tolerance Effects 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 235000013339 cereals Nutrition 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 240000005109 Cryptomeria japonica Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 241000589158 Agrobacterium Species 0.000 description 5
- 102000006395 Globulins Human genes 0.000 description 5
- 108010044091 Globulins Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108091036066 Three prime untranslated region Proteins 0.000 description 5
- 240000008042 Zea mays Species 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 230000000172 allergic effect Effects 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000001938 protoplast Anatomy 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 101000742090 Bacillus subtilis (strain 168) ATP-dependent alanine/valine adenylase Proteins 0.000 description 3
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000004262 Food Hypersensitivity Diseases 0.000 description 3
- 206010016946 Food allergy Diseases 0.000 description 3
- 108700023224 Glucose-1-phosphate adenylyltransferases Proteins 0.000 description 3
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 3
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000218922 Magnoliophyta Species 0.000 description 3
- 101710176384 Peptide 1 Proteins 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 244000098338 Triticum aestivum Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000020932 food allergy Nutrition 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- INOZZBHURUDQQR-AJNGGQMLSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 INOZZBHURUDQQR-AJNGGQMLSA-N 0.000 description 2
- BKWMKTIGFLPGOV-RABCQHRBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO BKWMKTIGFLPGOV-RABCQHRBSA-N 0.000 description 2
- 241000219495 Betulaceae Species 0.000 description 2
- 102000012286 Chitinases Human genes 0.000 description 2
- 108010022172 Chitinases Proteins 0.000 description 2
- 241000218691 Cupressaceae Species 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 240000008620 Fagopyrum esculentum Species 0.000 description 2
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 108010000614 SEKDEL sequence Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- 238000003277 amino acid sequence analysis Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013568 food allergen Substances 0.000 description 2
- -1 for example Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 108010041601 histidyl-aspartyl-glutamyl-leucine Proteins 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229940023041 peptide vaccine Drugs 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101710102211 11S globulin Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 101710190853 Cruciferin Proteins 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 101150039033 Eci2 gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 244000207740 Lemna minor Species 0.000 description 1
- 235000006439 Lemna minor Nutrition 0.000 description 1
- 244000297531 Lespedeza cuneata Species 0.000 description 1
- 241000209510 Liliopsida Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 240000004928 Paspalum scrobiculatum Species 0.000 description 1
- 235000003675 Paspalum scrobiculatum Nutrition 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 102000007001 Period Circadian Proteins Human genes 0.000 description 1
- 108010047728 Period Circadian Proteins Proteins 0.000 description 1
- IAJOBQBIJHVGMQ-UHFFFAOYSA-N Phosphinothricin Natural products CP(O)(=O)CCC(N)C(O)=O IAJOBQBIJHVGMQ-UHFFFAOYSA-N 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010016634 Seed Storage Proteins Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000011681 asexual reproduction Effects 0.000 description 1
- 238000013465 asexual reproduction Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000021305 genetically modified rice Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- IAJOBQBIJHVGMQ-BYPYZUCNSA-N glufosinate-P Chemical compound CP(O)(=O)CC[C@H](N)C(O)=O IAJOBQBIJHVGMQ-BYPYZUCNSA-N 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 108010002685 hygromycin-B kinase Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000014639 sexual reproduction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
- C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/196—Products in which the original granular shape is maintained, e.g. parboiled rice
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a method for accumulating an allergen-specific ⁇ cell antigenic determinant in a plant, and a plant in which the antigenic determinant is accumulated.
- T-cell peptide derived from allergen In recent years, attention has been paid to beptide immunotherapy which administers T-cell peptide derived from allergen.
- the mechanism of action may be unresponsiveness or deletion of allergen-specific helper type II T cells.
- Veptide immunotherapy using T-cell epitopes generally does not contain allergic B-cell epitopes and does not bind to allergen-specific IgE antibodies, so the side effects of conventional desensitization therapy Is less likely to occur and is safe.
- T-cell peptides derived from cedar pollinosis allergens also show high reactivity to specific T cells, suggesting that they have the ability to induce T cell unresponsiveness by oral administration (For example, see Non-Patent Documents 1 to 4). Based on this, the application of T cell epitope peptide as a peptide vaccine for the treatment of cedar pollinosis was expected, but the actual application form has not been developed yet. It was state.
- a method for accumulating the allergen-specific T cell epitope in a practically useful plant, and a useful accumulated plant and the like have not been known so far.
- Non-Patent Document 1 Hirahara 'Kazuki (Kazuki Hirahara) et al., J. Allergy Cl in.Immunol., Vol. 102, p. 961-967, 1998
- Non-Patent Document 2 Hirahara 'Kazuki (Kazuki Hirahara) et al., J. Allergy Cl in.I imunol., Vol. 108, p. 94-100, 2001
- Non-Patent Document 3 Sone 'Toshio Sone et al., J. Immunology, p. 448-457, 1998
- Non-Patent Document 4 Yoshitomi 'Tomomi (Tomomi Yoshi tomi) et al., Immunology, Vol. 107, p. 517-522, 2002 Disclosure of the Invention
- an object of the present invention is to integrate a T-cell epitope peptide as a peptide vaccine to treat or prevent cedar pollinosis.
- an object of the present invention is to provide a method for accumulating allergen-specific T cell epitopes in a plant, and to provide a plant in which the epitope is accumulated.
- the present inventors have conducted intensive research to solve the above problems.
- the present inventors have proposed a T cell epitope composed of seven major 12 to 19 amino acid residues of human, presented by antigen presenting cells (macrophage) found in cedar pollen allergens Cryj 1 and Cryj 2
- a human gene encoding a hybrid peptide (7 crp) linked to Escherichia coli and expressing this gene specifically in endosperm, the edible part of rice, accumulates T-cell epitope peptides. Rice was successfully developed.
- the method of accumulating human epithelial cells in rice endosperm includes a method of directly accumulating 7crp peptide in seeds, and a method of inserting the 7crp peptide into the variable region of glutelin, a major storage protein of rice.
- a method was developed to express and accumulate as part of the glutelin storage protein.
- allergen epitope peptides accumulated in edible parts are highly accumulated, they can be taken orally to treat allergen-derived allergic reactions by an immune tolerance mechanism. Become.
- the amount of T-cell epitope-linked peptide required to induce immune tolerance in humans is 7.5 mg (2.5. 5 / ig) 2250 mg estimated.
- seeds producing T-cell epitope-linked peptide for seeds accumulating 30/2 g per grain, the weight of one seed is about 20 mg
- 3.75 mg to 375 mg is required,
- 2.5 g to 250 g is sufficient, so it can be said that a daily dietary amount (100 g to 150 g) is sufficient for immune tolerance.
- the rice that produces the T-cell epitope-linked peptide developed in the present invention is strongly expected to actually function as an eating vaccine against cedar pollinosis. Furthermore, since the 7crp peptide accumulated by the method of the present invention has a different accumulation site in endosperm, it is expected that the induction mechanism via the mucosal immune system will be slightly different.
- Peptides produced in seeds are extremely stable and do not degrade and lose their activity for more than a year, even if the seeds are left at room temperature. Also, compared to tank culture, it is easier to control the production volume. The production can be controlled by the number of seeds sown.
- the method developed by the present inventors succeeded in producing, for the first time, a useful rice (rice) in which T cell epitopes were highly accumulated in endosperm.
- ⁇ rice in which T-cell epitopes are accumulated in endosperm '' produced by the method of the present invention has an effect of actually inducing immune tolerance through a mouse efficacy evaluation test. I found something. That is, the above rice of the present invention was shown to have a sufficiently high possibility of alleviating hay fever.
- the present inventors have proposed a method for accumulating allergen-specific ⁇ -cell epitopes in plants, and a method for accumulating the allergen-specific ⁇ -cell epitopes (for example, allergen-specific ⁇ -cell epitopes Rice that was highly integrated in the endosperm), and completed the present invention. More specifically, the present invention provides [1] a DNA having a structure in which any one of the following DNAs (a) to (c) is arranged under the control of a storage protein promoter:
- the storage protein promoter is a promoter selected from the group consisting of glutelin GluB-1 promoter, daltellin GluB-4 promoter, 10 kD prolamin promoter, and 16 kD prolamin promoter; (1) to (3) The DNA according to any one of the above,
- a host cell that retains the DNA of any one of (1) to (5) or the vector of (6);
- (8) a method for accumulating allergen-specific T-cell epitopes in a plant, A method comprising introducing the DNA according to any one of (1) to (5) or the vector according to (6) into a plant,
- a method for accumulating T cell epitopes in plants comprising the following steps (a) to (c):
- a method of collecting T cell epitopes on a plant comprising the following steps (a) and (b):
- the plant is an angiosperm, the method according to any one of (8) to (16), (18) the angiosperm is a gramineous plant, the method according to (17),
- a seed according to (24), which is characterized by being stable to heat (26) a rice produced by the method according to (19), More preferably, an allergic agent comprising rice having cell epitope accumulated in endosperm, the seed according to [27] [24] or [25], or the rice according to [26] as an active ingredient.
- an allergic agent comprising rice having cell epitope accumulated in endosperm, the seed according to [27] [24] or [25], or the rice according to [26] as an active ingredient.
- the present invention provides a method for accumulating allergen-specific ⁇ -cell epitopes in plants.
- the present invention is a method characterized in that a ⁇ cell antigenic determinant (epitope) presented by an antigen presenting cell (macrophage) using an allergen as an antigen is expressed in a plant.
- allergen-specific ⁇ -cell epitope refers to ⁇ -cell epitope derived from an allergen, and more specifically, -cell epitope ( ⁇ ) presented by antigen-presenting cells using allergen as an antigen.
- Allergens generally refer to antigens that cause allergic diseases (allergic reactions).
- the allergen in the present invention is not particularly limited, but includes not only naturally occurring substances such as proteins and glycoproteins, but also synthesized proteins. The quality is also included.
- Allergens in the natural world include, for example, pollen (cedar, cypress, alder, bush clover, grass duck pollen, etc.) allergens, and allergens derived from animals (dogs, cats, mice, rats, pomas, pests, etc.) And insect allergens, parasite allergens, food allergens, and power beer allergens.
- Examples of the allergen suitably used in the present invention include pollen allergens, mite allergens, food allergens and the like, and more preferably cedar pollen-derived pollen allergens. More specifically, Cryj 1 (H. Yasueda, Y. Yui, T. Shimizu, T. Shida.Isolation and partial characterization of the major allergen from Japanese cedar (Cryptomeria japonic a) pollen. J. Allergy Clin. Immunol. 1983; vol. 71,. 77-86 .; TS one, N. Komiyama, K Shimizu, T Kusakabe, K.
- Cry j II the second major allergen of Japanese cedar pollen.
- Examples of the “food” include buckwheat, wheat, eggs, milk, peanuts, and the like.
- the T cell antigenic determinant (sometimes referred to as “epitope” or “epitope peptide”) used in the above method is usually degraded by the antigen-presenting cells in the above allergen. It is an antigen peptide (subjected to antigen treatment) and presented on the cell surface, or a partial region of the peptide. That is, the amino acid sequence of the epitope of the present invention is not particularly limited as long as it is a peptide that can be recognized as an allergen-derived antigen peptide by T cell receptor.
- the T-cell epitope of the present invention is not particularly limited, but is preferably a human E-cell epitope.
- the peptide length of the epitope (epitope peptide) of the present invention varies depending on the type of the allergen, etc., it is difficult to specify the peptide length. However, it usually comprises about 10 to 25 amino acid residues, more preferably Consists of 12 to 19 amino acid residues.
- the epitope of the present invention is preferably one in which two or more human ⁇ -cell epitopes are linked. By linking two or more, the effect of inducing the immune tolerance mechanism is expected to increase. More specifically, as the epitope of the present invention, a peptide in which seven epitopes are linked (for example, 7crp (SEQ ID NO: 1) and the like) can be suitably used as shown in Examples described later. In addition, a peptide in which a plurality of linked peptide peptides such as 7crp and the like are further linked twice (SEQ ID NO: 2), three times and multiple times in tandem can also be used in the present invention.
- 7crp SEQ ID NO: 1
- SEQ ID NO: 2 a peptide in which a plurality of linked peptide peptides such as 7crp and the like are further linked twice
- a plurality of epitopes are preferably used in the present invention so as to have an effect on many people.
- the epitope of the present invention is expressed in a plant under the control (control) of a storage protein promoter. More specifically, first, a DNA encoding an allergen-specific human T-cell epitope peptide was obtained (step (a)), and then the 5′-end of the DNA obtained in step (a) was obtained. And a DNA encoding a storage protein signal sequence and / or a DNA encoding an endoplasmic reticulum anchoring signal sequence at the 3 'end (step (b)). Next, the DNA of the above (b) is expressed in plants under the control of the storage protein promoter overnight (step (c)).
- the storage protein in the present invention generally refers to a protein stored in seeds mainly as an energy source in plants.
- Examples of storage proteins include simple proteins glutelin and prolamin be able to.
- glutelin can be shown.
- the accession number of the gene encoding glutelin in GenBank is X54314 (0. sat iva GluB-1 gene for glutel in), and the accession number of the cDNA of the gene is X05664.
- the promoter in the present invention can be used by those skilled in the art by appropriately selecting or modifying a known promoter depending on the type of the gene to be expressed or the type of the cell to be introduced.
- the storage protein Promo overnight can be utilized.
- An example of the storage protein promoter used in the present invention is the daltelin GluB-1 promoter.
- the length of the promoter is usually 1.3 kb or more, preferably 2.31 ⁇ or more, but is not particularly limited as long as it has a function equivalent to that of the promoter of the present invention.
- a 2.3k GluB-1 promoter can be mentioned.
- increasing the length of the promoter will increase the efficiency of expression and accumulation of the protein encoded by the downstream gene.
- Dalterin GluB-1 promoter has a strong promoter activity, and therefore can be suitably used for rice or cereals other than rice.
- promoters examples include, in addition to the above-mentioned dalterin GluB-1, for example, glutelin GluB-4 promoter, 10 kD prolamin promoter, and 16 kD prolamin promoter. it can. These promoters can be suitably used in the method of the present invention, as will be shown in Examples described later.
- the information on the nucleotide sequence of the promoter described above can be appropriately obtained from patent documents or academic documents, or public databases such as GenBank. (Japanese Patent Application No. 2003-37 7 8 15; Plant Biotechnology Journal. 2, 113-125 (2004) LQ Qu, and F.
- the DNA encoding the allergen-specific human T cell epitope peptide in the above step (a) includes genomic DNA, cDNA, and chemically synthesized DNA.
- genomic DNA and cDNA from an organism from which an allergen is derived (eg, rice or the like) can be performed by a person skilled in the art using conventional methods.
- genomic DNA for example, genomic DNA is extracted from the organism from which the allergen is derived, and a genomic library (plasmids, phages, cosmids, BAC, PAC, etc. can be used as vectors) is created.
- colony hybridization or plaque hybridization was performed using a probe prepared based on the nucleotide sequence information of the DNA encoding the allergen-specific human T-cell epitope peptide. It is possible to prepare by carrying out. It is also possible to prepare by preparing a primer specific to the DNA encoding the allergen-specific human T-cell epitope peptide of the present invention and performing PCR using the primer.
- cDNA for example, cDNA is synthesized based on mRNA extracted from the organism from which the allergen is derived, and inserted into a vector such as ⁇ ZAP to create a cDNA library, which is then developed. Then, it can be prepared by carrying out PCR or plaque hybridization in the same manner as described above, or by carrying out PCR.
- the DNA encoding the epitope peptide of the present invention can be artificially synthesized as appropriate, based on the amino acid sequence information of the peptide.
- the target DNA can be synthesized in consideration of amino acid degeneracy and the like with reference to codons frequently used in storage protein genes.
- the epitope peptide of the present invention for example, 7crp
- the DNA sequence encoding the peptide is frequently used in the rice seed storage protein gene so that it can be efficiently translated in rice seeds. Can be used.
- Codons preferably used in the present invention are not particularly limited. However, for example, the codons in Table 1 can be shown.
- the storage protein signal (peptide) sequence in the above step (b) various known storage protein signal sequences can be used as appropriate.
- Information on the amino acid sequence of the storage protein signal sequence of the present invention is as follows. For those skilled in the art Can be easily obtained from publicly known documents and the like.
- the storage protein signal has a function of transferring the epitope peptide of the present invention to the endoplasmic reticulum, and has a role of preventing the peptide from being transferred to the cytoplasm and being degraded or secreted out of the cell. .
- a signal sequence of glutelin (Glu B-1) protein can be preferably used. Specifically, the following sequences can be shown as storage protein signal sequences that can be used in the present invention.
- MASSVFSRFS IYFCVLLLCHGSMA SEQ ID NO: 3
- MAS INRP IV FFTVCLFLLCDGSLA (SEQ ID NO: 4), which is the signal sequence of other glutelin (GluA-2), or MASKVVFFAAALMAAMVA IS GA Q (SEQ ID NO: 5), which is a 26 kD globulin signal sequence It is also possible to use.
- the ER-retention signal sequence of the present invention for example, a KDEL sequence, SEKDEL sequence, or HDEL sequence can be used, but is not particularly limited thereto.
- the DNA encoding the endoplasmic reticulum anchoring signal sequence of the present invention may contain, for example, a 3 ′ untranslated region downstream of the DNA encoding the KDEL sequence.
- the 3 ′ untranslated region is not particularly limited, but is usually about 100 to 1000 bp in length.
- the DNA encoding the endoplasmic reticulum anchoring signal sequence of the present invention a DNA obtained by combining a DNA encoding the KDEL sequence and a region containing about 650 bp of the dalterin 3 ′ untranslated region downstream of the DNA is used. Can be shown. Generally, a 3 'untranslated region of a storage protein gene such as glutelin can be suitably used as the 3' untranslated region. It is also possible to use the N0S terminator, or 35SCaMV evening / mining evening.
- the above sequence has a function of improving the amount of foreign protein accumulated in storage sites such as seeds.
- the DNA encoding the storage protein signal sequence or the endoplasmic reticulum anchoring signal sequence may be appropriately prepared by a person skilled in the art by considering the degeneracy of the amino acid sequence and the like. It can be obtained (synthesized) using an NA synthesizer or the like.
- DNA encoding the storage protein signal sequence to the 5 ′ end of the DNA obtained in step (a) and addition of DNA encoding the endoplasmic reticulum anchoring signal sequence to the 3 ′ end are known to those skilled in the art. It can be performed using known genetic engineering techniques.
- the above “5 ′ end” or “3 ′ end” is generally defined as an end that shows a direction in which transcription is received from a promoter in the order of 5 ′ end ⁇ 3 ′ end. Therefore, the end of the DNA on the promoter side (direction) is defined as “5 ′ end”.
- step (c) in order to express DNA in a plant under the control of the storage protein promoter, the storage protein promoter and the DNA are usually linked so that the DNA can be expressed. It can be carried out by introducing DNA into a plant. Placing a desired MA to be expressed downstream of the promoter so as to be under the control of the promoter can be easily performed by those skilled in the art using general genetic techniques.
- Plants capable of accumulating epitopes by the method of the present invention are not limited to specific species, but are usually angiosperms, preferably monocotyledons, and more preferably gramineous plants It is.
- the plant of the present invention may be a dicotyledonous plant.
- a seed promoter of a dicotyledonous plant for example, cotyledon-embryo-specific
- the grasses include cereals such as rice, wheat, corn, corn and the like, and rice is most preferred as the plant of the present invention.
- the epitope of the present invention can be easily introduced into the body by eating the site by humans. It is possible to incorporate. For example, when the plant of the present invention is rice If it is, it is possible to accumulate the epitope in the endosperm.
- the method of the present invention is a useful method characterized in that T cell epitopes are preferably accumulated in edible parts of plants.
- the edible portion differs depending on the type of plant, and is not necessarily limited. Examples thereof include seeds, leaves, roots, and the like.
- accumulation site More specific examples include rice, wheat, corn, etc., endosperm, soybean, etc. cotyledon, embryo, potato, etc. tuber, carrot root, tomato, banana, etc. .
- a DNA capable of expressing the epitope of the present invention in a plant body used in the above method of the present invention is also included in the present invention.
- Examples of such DNA include DNA having a structure in which any of the following DNAs is arranged under the control of a storage protein promoter.
- DNA is placed under the control of a storage protein promoter
- the storage protein promoter is linked to the DNA so that the DNA can be expressed. In other words, it indicates that the promoter and the downstream DNA are linked so that the expression of the downstream DNA is induced with the activation of the promoter.
- a method for inserting a T cell epitope into a storage protein and expressing and accumulating the epitope as a part of the storage protein.
- DNA encoding an allergen-specific T-cell peptide is obtained, and then the DNA is inserted into a DNA region encoding a variable region of a plant storage protein. And express it.
- the site in the storage protein into which the epitope is introduced is preferably a variable region of the storage protein.
- the term “variable region” refers to a region that is highly mutated during the evolution process depending on the type and length of the amino acid sequence. Therefore, since the insertion of the foreign peptide does not affect the three-dimensional structure, it is possible to accumulate the foreign peptide as a part of the stored protein and to act as a part of the stored protein. Therefore, it is possible to accumulate at the same storage site as the introduced storage protein.
- variable region of the present invention examples include, for example, rice glutelin, three sites of acidic subunit (in the case of daltellin GluB-1 gene, a region of amino acids 140, 210, 270 to 310 from the N-terminus) ), And the C-terminal region of a basic subunit.
- a desired foreign peptide to be expressed can be inserted into these regions ( and one of the above-described epitopes of the present invention can be inserted into each of the variable regions).
- glutelin belongs to the 11S globulin family (a member of the soybean dalicynin protein globulin), and even if it is a protein other than glutelin belonging to this family, A foreign peptide can be inserted into the variable region exemplified in (2) except for rice globulin (a member different from protein globulin). Can insert an epitope into the variable region about 110 from the N-terminus.
- One method is to insert one (lx7crp) or two (2x7crp) tandems of the 96 amino acid sequence of the 7crp coding region between them (acidic subunit coding region) and express it as part of daltelin.
- insertion of the DNA encoding the epitope of the present invention into the DNA region encoding the variable region of the storage protein can be easily performed by those skilled in the art using general genetic engineering techniques. That is.
- a DNA encoding a polypeptide having a structure in which the T cell epitope used in the above method is inserted into a storage protein is also included in the present invention.
- examples of such DM include, for example, (c) a structure in which an allergen-specific T-cell epitope peptide is inserted into the amino acid sequence (preferably, a variable region) of a storage protein under the control of a storage protein promoter.
- a promoter inherent in the upstream of the storage protein can be used as the promoter.
- the present invention also provides a vector containing the DNA of the present invention, and a host cell carrying the DNA of the present invention or the vector of the present invention.
- the vector of the present invention is not particularly limited as long as it stably holds the DNA of the present invention.
- the vector of the present invention can be prepared by those skilled in the art by appropriately considering the type of a plant to be expressed and clone the DNA into various known vectors.
- the insertion of the DNA of the present invention into a known vector can be performed by a conventional method, for example, by a ligase reaction using a restriction enzyme site (Current protocol s in Molecular Biology edit. Ausubel et al. (1987)). ) Publish. John Wiley & Sons. Section 11. 4-11.
- the vector pGluBsig7CrpKDEL described in Examples described later can be mentioned.
- the vector of the present invention can be used in the method of accumulating epitopes of the present invention, and is useful as a vector for producing a T cell epitope-enriched plant.
- the host cell into which the vector of the present invention is introduced is not particularly limited, and various known cells may be used depending on the purpose.
- the term "host cell” includes various forms of plant cells, and the forms include all types of plant cells that can be regenerated into plants. For example, suspension culture cells, protoplasts, shoot primordia, many Includes, but is not limited to, buds, hairy roots, calli, etc.
- the host cell of the present invention does not necessarily need to be a plant-derived cell, for example, Escherichia coli, yeast, or an animal cell. Good.
- the introduction of the vector into the host cell can be performed, for example, by the calcium phosphate precipitation method or the electropulse perforation method (Current protocol s in Molecular Biology editor. Ausubel et al. (1987) Publish. John Wiley & Sons. Section 9 1-9. 9), ribofectamine method (manufactured by GI BCO-BRL), microinjection method and the like can be carried out.
- the present invention relates to the above MA or vector of the present invention.
- the present invention relates to a method for accumulating a T cell epitope in a plant, which is characterized by being introduced into a plant, and a method for producing a plant accumulating a T cell epitope, which is characterized by introducing the DNA or vector of the present invention to a plant. .
- a method for producing a transgenic plant in which T cell epitopes are accumulated using the method of the present invention and a method for producing rice in which T cell epitopes are accumulated using the method of the present invention.
- a manufacturing method is provided.
- the DNA of the present invention is introduced into an appropriate vector, and The cells are introduced into cells, and the transformed plant cells thus obtained are allowed to grow (regenerate).
- the growth (regeneration) of the plant can be performed by a method known to those skilled in the art depending on the type of the plant cell (see Toki et al. (1995) Plant Physiol. 100: 1503-1507).
- a method for producing a transformed plant is to introduce a gene into protoplasts using polyethylene glycol and grow (regenerate) the plant (Datta, SK (1995) In Gene Transfer To Plants).
- the plant into which the DNA or vector of the present invention is introduced may be an explant, or cultured cells may be prepared from these plants and introduced into the obtained cultured cells.
- the “plant cells” of the present invention include, for example, plant cells such as leaves, roots, stems, flowers and scutellum in seeds, calli, suspension cultured cells and the like.
- the DNA or vector of the present invention contains an appropriate selection marker gene, or contains a selection marker gene. It is preferable to introduce the plasmid vector into a plant cell together with the plasmid vector.
- Selectable marker genes used for this purpose include, for example, the hygromycin phosphotransferase gene, which is resistant to the antibiotic hygromycin, the neomycin phosphotransferase gene, which is resistant to kanamycin or gentamicin, and the herbicide phosphinothricin And an acetyltransferase gene which is resistant to E. coli.
- the plant cells into which the recombinant vector has been introduced are placed on a known selection medium containing an appropriate selection agent according to the type of the introduced marker gene and cultured. As a result, transformed plant culture cells can be obtained.
- the plant regenerated from the transformed cells is then cultured in a conditioned medium. After that, if the regenerated acclimated plant is cultivated under normal cultivation conditions, a plant is obtained, and it is possible to obtain seeds by maturing and fruiting.
- the presence of the DNA of the present invention introduced into the transformed plant thus grown (regenerated) can be confirmed by a known PCR method or Southern hybridization method. In this case, extraction of the DNA from the transformed plant can be carried out according to a known method of J. Sambrook et al. (Molecular Cloning, 2nd edition, Cold Spring Harbor press, 1989).
- the present invention provides a transgenic plant (transformed plant) in which T-cell epitopes are accumulated, which is produced by the method of the present invention, and cells derived from the plant.
- a plant in which cedar pollen allergen human T-cell epitope is accumulated in seeds by the method of the present invention is useful as a cedar pollinosis alleviating crop.
- progeny can be obtained from the plant by sexual or asexual reproduction.
- a propagation material for example, seeds, fruits, cuttings, tubers, tubers, roots, strains, calli, protoplasts, etc.
- the present invention includes progeny or clones of transgenic plants in which the T cell epitopes produced by the method of the present invention have accumulated, cells derived from the transgenic plants or progeny or clones, propagation material, and seeds.
- the seed of the present invention is expected to have heat stable properties.
- rice (rice) in which allergen-specific human T-cell epitopes are accumulated in endosperm can be mentioned.
- the present invention provides a food composition or a food or drink characterized by having a preventive, therapeutic or palliative action for an allergic disease.
- the food composition or the food or drink of the present invention may be a plant produced by the method of the present invention, in which the epitope is accumulated (for example, seeds or rice), or an extract containing the epitope extracted therefrom, or It is composed of these processed products.
- a food composition for treating or preventing an allergic disease comprising a seed or rice in which epitope obtained by the method of the present invention has been accumulated, or a component extracted therefrom, is also provided.
- the ⁇ composition '' of the present invention does not necessarily require the addition of a plurality of substances to the seed or rice, and may be a food comprising only the seed or rice of the present invention. Good.
- the food composition or food or drink of the present invention can be subjected to a cooking method such as heating.
- a cooking method such as heating.
- additives such as stabilizers, preservatives, coloring agents, fragrances, and vitamins are appropriately added to the above-mentioned food composition and mixed, and tablets, granules, granules, powders, capsules, liquids, It can be in a form suitable for creamy compositions such as beverages.
- an allergen eg, Japanese cedar pollen allergen
- a preventive, therapeutic, or palliative effect on an allergic disease eg, hay fever
- Food and beverages containing accumulated rice can be listed.
- the foods and drinks include processed products using the rice of the present invention as a raw material, for example, rice cake (dango, cut rice cake, shinshin powder, white ball powder), rice cracker, rice flour (bifun), sake, brown rice tea, rice bran , Class I (udon) and the like.
- the food or drink of the present invention is preferably a food or drink that is labeled to be used for the prevention, treatment or alleviation of an allergic disease (for example, hay fever).
- an allergic disease for example, hay fever
- the present invention also includes a pharmaceutical composition for treating or preventing an allergic disease, comprising a site (seed, rice, etc.) in which a plant-derived epitope produced by the method of the present invention has accumulated as an active ingredient.
- an allergic disease is a general term for diseases in which an allergic reaction is involved.
- Representative allergic diseases include, for example, hay fever, bronchial asthma, food allergy, allergic rhinitis, or insect allergy.
- allergic diseases can usually be distinguished from diseases showing type I-IV allergic reactions.
- Particularly limited as the allergic disease of the present invention although not required, it is preferably type I allergy.
- the type I allergy include hay fever, mite allergy, bronchial asthma, food allergy, allergic monorhinitis and the like.
- Preferable examples of the allergic disease of the present invention include cedar pollinosis and mite allergy.
- the method of the present invention using allergen-specific epitopes corresponding to the above-mentioned diseases is expected to be applied to a treatment called so-called tailor-made medicine.
- FIG. 1 is a diagram and a photograph showing the results of analysis of the expression of 7Crp in a transformant using the vector of the present invention, pGluBsig7CrpKDEL.
- the upper diagram shows the structure of the plasmid pGluBsig7CrpKDEL.
- 7Crp is expressed by the control of the 2.3k promoter of the glutelin GluB-1 gene.
- the middle figure shows the results of quantification of the amount of 7Crp accumulated in the ripe transformant seeds obtained.Compared with seeds with strain numbers # 1, # 10, # 15, # 17, # 31, # 34, etc. A very high accumulation amount is observed.
- the lower panel is a photograph showing the results of Northern analysis of the transcript of the 7Crp gene in the seeds (at about 15 days after flowering) of the ripening stage transformants of the TO generation.
- FIG. 2 is a diagram and a photograph showing the results of 7Crp expression analysis in a transformant using the vector of the present invention, pGluBsig7Crp.
- the upper diagram shows the structure of plasmid pGluBsig7Crp, in which the KDEL sequence is not added to the 3 'end of 7Crp.
- the middle panel shows the results of quantification of the amount of accumulated 7Crp in the obtained mature seeds of the transformant. Compared to the case where the KDEL sequence is added to the 7Crp 3 'end in FIG. 1, the accumulation amount of 7Crp is reduced.
- the lower panel is a photograph showing the results of Northern analysis of the transcript of the 7Crp gene in the seeds during the ripening stage of the T0 transformed rice.
- FIG. 3 is a photograph showing the result of Southern analysis of genomic DNA of a transformant using the vector of the present invention, pGluBsig7CrpKDEL.
- Genomic DNA (lO ⁇ g) extracted from leaves of untransformed rice and strains # 1, # 10, # 17 and # 34 were digested with the restriction enzyme Sac I. After digestion and separation by 0.9% (w / v) agarose electrophoresis, the DNA was transferred to a nylon membrane. Thereafter, the 7Crp gene was detected using the full-length DNA of the 7Crp gene labeled with a radioisotope as a probe.
- FIG. 4 is a photograph showing the expression patterns of glutelin and 7Crp peptide during the seed ripening process by Westin analysis.
- the vector of the present invention pGluBs ig7CrpKDEL, the whole protein of the seed of the transformant # 10 was extracted at 5, 10, 15, 20, and 25 days after flowering, separated by SDS-PAGE, and transferred to a PVDF membrane. Transcribed. Thereafter, daltelin or 7Crp peptide was detected using an anti-gluterin antibody or an anti-7Crp antibody.
- FIG. 5 is a photograph showing the expression patterns of the daltellin gene and 7Crp gene during the seed ripening process by Northern analysis.
- the total RNA of each of the seed, leaf and stem of the transformant # 10 by the vector pGluBsig7CrpKDEL of the present invention was extracted, separated by agarose gel electrophoresis, and transferred to a nylon membrane. Thereafter, transcripts of dalterin or 7Crp were detected using glutelin or 7Crp gene full-length DNA labeled with a radioisotope as a probe.
- 25S and 17S rRNAs are visualized.
- the transcripts of glutelin and in the lower panel, 7Crp are shown.
- FIG. 6 is a photograph showing the result of analyzing the site of accumulation of 7Crp peptide in the seed of transformant # 10 by the vector pGluBsig7CrpKDEL of the present invention.
- the figure on the left shows the results of Western analysis using an anti-7Crp antibody for protein fractions extracted from endosperm, embryo, spleen, and leaf.
- the figure on the right shows the results of tissue immunostaining of cross sections of ripened seeds using an anti-7Crp antibody.
- an anti-Peagle IgG alkaline phosphatase-labeled antibody was used.
- FIG. 7 is a photograph showing the results of comparing the amount of 7Crp peptide accumulated in seeds of Tl, ⁇ 2, and ⁇ 3 generations of a transformant obtained by the vector of the present invention, pGluBsig7CrpKDEL.
- pGluBsig7CrpKDEL a transformant obtained by the vector of the present invention.
- total proteins were extracted from seeds of each generation. Western analysis was performed using an anti-7Crp antibody.
- FIG. 8 is a photograph showing the result of analyzing the stability of the 7 Crp peptide accumulated in the seeds of the transformant with the vector pGluBsig7CrpKDEL of the present invention to heat treatment.
- FIG. 9 is a photograph showing an analysis result of an N-linked sugar chain for 7Crp peptide accumulated in a transformant seed by the vector pGluBsig7CrpKDEL of the present invention.
- N-glycosidase F N-linked glycoprotein transferrin and liponuclease B were used as control substrates for the glycosidase reaction.
- the change in substrate molecular weight before and after the reaction with the enzyme was analyzed by SDS-PAGE.
- 7Crp peptide and substrate protein were visualized by Western analysis using an anti-7Crp antibody, and in the right figure, by staining with CBB.
- FIG. 10 is a photograph showing the result of analyzing the effect of 7Crp peptide expression on rice allergen protein expression. After separating all proteins extracted from the seeds of the non-transformed rice and the transformed strain line # 10 by SDS-PAGE, Western analysis was performed using an antibody that specifically recognizes each of the rice allergen proteins. Allergen proteins were detected.
- FIG. 11 is a diagram and a photograph showing the results of analyzing the expression of 7CrP in a transformant using the vector pAGPases ig7CrpKDEL of the present invention.
- the upper figure shows the structure of the plasmid pAGPase sig7Cr pKDEL. Expression of 7Crp is controlled by the promoter of ADP glucose pyrophosphorylase.
- the middle panel shows the results of quantification of the amount of accumulated 7 Crp in the obtained mature seeds of the transformant. 2. Although the amount of 7Crp accumulated is smaller than when the 3 kGluB-1 promoter was used, 7Crp accumulation is observed in many strains.
- the figure below shows the analysis of the transcript of the 7Crp gene in the ripening seeds of the TO generation transformants. It is the result of Northern analysis.
- FIG. 12 is a diagram and a photograph showing the results of analysis of the expression of 7Crp in a transformant using the vector of the present invention, pREE99 2 ⁇ 7Crp.
- the upper figure shows the structure of plasmid PREE99 2x7Crp.
- Two 7Crps are inserted in tandem into the variable region of the cDNA clone pREE99 of the glutelin GluA-2 gene.
- the middle panel shows the results of quantification of the amount of 7Crp accumulated in the obtained matured transformant.
- the two 7Crps inserted into the variable region accumulate as a part of glutelin.
- the figure below shows the results of Northern analysis in which the transcript of the 7Crp gene inserted into PREE99 was analyzed in the seeds of the TO generation transformant at the ripening stage.
- FIG. 13 is a diagram and a photograph showing a comparison of the accumulation amount of T cell epitope peptide depending on the promoter.
- the upper part is a diagram showing the structure of a gene using each promoter.
- the lower part is a gel electrophoresis photograph comparing the accumulation amount of the T cell epitope peptide.
- FIG. 14 is a diagram and a photograph relating to the comparison of the amount of accumulation of T cell peptide by the localization site.
- the upper part is a diagram showing the structure of each gene. ZE ”.
- the lower part is a photograph comparing the amount of accumulation of the T cell epitope peptide depending on the localization site.
- FIG. 15 is a graph showing the results of induction of immunological tolerance by oral administration of recombinant rice expressing the T cell epitope peptide (7crp).
- the left graph is for T cell proliferative responses, and the right graph is for IgE levels.
- Example 1 Preparation of T cell epitope-coupled peptide expression plasmid and introduction into rice grass -1-An expression plasmid for expressing the cedar pollen allergen T cell epitope-linked peptide in rice seeds was prepared.
- the promoter of glutelin GluB-1 which is a major protein of rice seed (previously, 1.3 kb was used, but in the present invention, 2.3 kb was used; the promoter activity was increased by more than 5-fold), signal sequence and T cell
- the expression plasmid pGluBs ig7CrpKDEL is added by adding the ER anchoring signal KDEL sequence, which has the function of improving the accumulation of foreign gene products in seeds, to the 3 'end of the T-cell peptide-linked peptide.
- the promoter of glutelin GluB-1 which is a major protein of rice seed (previously, 1.3 kb was used, but in the present invention, 2.3 kb was used; the promoter activity was increased by more than 5-fold), signal sequence and T cell
- the expression plasmid pGluBs ig7CrpKDEL is added by adding the ER anchoring signal KDEL sequence, which has the function of improving the accumulation of foreign gene
- the nucleotide sequence of the DNA used in Examples having a 3Kb GluB-1 promoter sequence, a glutelin signal sequence, a 7crp epitope sequence, a KDEL sequence, and a 0.6K GluB-1 3 'sequence was represented by SEQ ID NO: 6.
- SEQ ID NO: 7 The amino acid sequence encoded by the DNA is shown in SEQ ID NO: 7.
- a plasmid pGluB7C rpKDEL in which the signal sequence was removed from pGluBsig7CrpKDEL and a plasmid pGluBs ig7Crp in which the KDEL sequence was removed were constructed.
- the 7crp peptide sequence was inserted into the variable region of the acidic subunit of glutelin (GluA-2), a major rice storage protein, to express the 7crp peptide as a part of glutelin.
- GluA-2 glutelin
- These plasmids were introduced into rice mushroom by the agrobacterium method, and transformants were selected using hygromycin resistance as an index.For these analyzes, more than 30 transformants were used for each construct. Was.
- Example 2 Detection of T-Cell Epitope-Linked Peptide in Transformant Seeds
- a total RNA fraction was collected from ripening seeds of a pGluB7CrpKDEL transformant having no signal sequence, and the T-cell epitope-linked peptide gene was used as a probe.
- Northern analysis was performed. As a result, transcripts were detected in 27 of the 32 lines, indicating that accumulation of T-cell epitope-linked peptides in seeds was expected. Therefore, proteins were extracted from ripe seeds, separated by electrophoresis, and visualized by CBB staining or Western blot analysis using specific antibodies. As a result, contrary to expectations, no signal of the T-cell epitope-linked peptide was detected.
- the T-cell peptide is not degraded in the rough endoplasmic reticulum but translocated to the cytoplasm and is degraded or secreted out of the cell. Can be considered
- transcript signals were detected in 29 of the 34 lines, and strong signals were observed particularly in lines 1, 5, and 10. ( Figure 1). Therefore, as a result of preparing and analyzing the whole protein from the ripe seed of line No. 10, a signal indicating a mobility of about 11,000 in molecular weight, which is not observed in the non-transformant, was detected.
- the accumulation amount of the T cell peptide-linked peptide in the seed was estimated.
- a T-cell epitope-linked peptide-histidine tag fusion protein expressed and purified in E. coli was used.
- relatively large numbers of T-cell epitope-linked peptides accumulated in strains such as Nos. 1, 10, 15, 17, 17, 31, and 34.
- 60 g of T-cell epitope-linked peptide equivalent to 4% of the total seed protein was observed to accumulate.
- pGluBsig7CrpI introduction of the DEL plasmid successfully produced a T cell epitope-linked peptide in rice seeds, and a signal sequence was required for the expression of T cell peptide-linked peptide. It was found to be essential, and that the addition of the KDEL sequence increased the amount of accumulation.
- Example 3 Detection of T-cell epitope-linked peptide introduced into rice Southern blot was performed to detect the T-cell epitope-linked peptide introduced into the genome of the transformant and identify its copy number.
- the genomic DNA of the transformant was analyzed by the following method. After preparing genomic DNA from the leaves of a transformant of a strain with a high expression level of the T cell epitope-linked peptide among the obtained transformants and treating with the restriction enzyme SacI, the T cell epitope was obtained. Southern blot analysis was performed using the entire region of the connecting peptide gene as a probe.
- the number of bands detected by Southern analysis corresponds to the number of copies of the T cell epitope-linked peptide gene introduced into the rice genome. I do.
- Southern blot analysis in the pGluBs ig7CrpKDEL transformant, two copies of T cell epitope-linked peptide gene were introduced into the transformant genome in 2 copies in No. 1, 4 copies in No. 10, and 2 copies in No. 17. It was confirmed that it was.
- the introduction of 2 copies of the gene at 17th, 1 copy at 19th, and 2 copies of the gene at 25th was confirmed (Fig. 3).
- Example 4 Expression characteristics of T cell epitope-linked peptide in rice seeds Highest expression level of T cell epitope-linked peptide in GluBs ig7CrpKDEL strain No. 10 seed, during seed ripening period Proteins were extracted from seeds at various time points after flowering and analyzed by Western blot to analyze the time course of expression of the T-cell epitope-linked peptide. T cell epitope-linked peptide signal after flowering Detected for the first time after 5 days, then gradually increased to ripe seed level. This result is in good agreement with the course of expression of GluB-1 protein analyzed using an antibody that specifically recognizes GluB_l protein (Fig. 4).
- Northern analysis analyzed the expression pattern of the 7crp gene during the seed ripening process. It was shown that the expression level of 7crp niRNA peaked 15 days after flowering and then decreased. This expression pattern was very similar to the daltellin gene promoter used to express the 7crp gene ( Figure 5). Also, as with proteins, expression in other tissues was not detected at the mRNA level.
- Tl of each of the pGluBs ig7CrpKDEL transformants Nos. 1, 10, and 17 was determined.
- # 2 and # 3 ripe seeds were collected, and Western blot analysis was performed on the protein extracted from the seeds.
- no change was observed in the signal of the ⁇ -cell epitope-linked peptide in the Tl, ⁇ 2, and ⁇ 3 seeds of all the No. 1, 10 and ⁇ lines. From this, even if the generation of the transformant is advanced, It was found that the vesicle epitope-linked peptide was produced in the seed and the amount of accumulation did not change (Fig. 7).
- Endoglycosidase is an enzyme having an activity of releasing a sugar chain by acting on a binding portion of the N-type sugar chain, and is used for analysis of the N-type sugar chain. When an N-type sugar chain is bound, the sugar chain is released from the protein by endoglycosidase, and the molecular weight of the protein changes before and after the reaction.
- the seed proteins were extracted, separated by two-dimensional electrophoresis, and transferred to PVDF membrane.
- a specific antibody was used to detect the signal of the peptide-coupled peptide.
- the ⁇ -cell epitope-linked peptide behaved as a basic protein. This result is consistent with the estimated isoelectric point determined from the amino acid sequence of the ⁇ -cell epitope binding peptide being 9.76.
- the spots of the ⁇ cell epitope-linked peptide were collected, and ⁇ terminal amino acid sequence analysis was requested.
- Example 6 Influence on rice allergen protein by introduction of cell epitope-linked peptide expression system
- An expression plasmid for expressing the cedar pollen allergen T-cell epitope-linked peptide in rice seeds was prepared. After ligation of the ADP glucose pyrophosphorylase promoter, the signal sequence to the T cell peptide 1, and the peptide, the KDEL sequence and the Nos-T sequence are added to the 3 'end to produce the expression plasmid pAGPase s. ig7CrpKDEL was constructed. The structure of the plasmid is shown in the upper part of FIG.
- the expression pattern of the 7crp gene was examined, it was also expressed in the endosperm and embryo or vascular bundle of the seed, and it was most strongly expressed in the seed as an organ.Therefore, the ADP darco-1 spirophosphorylase promoter-1 It was understood that it was possible to accumulate in.
- Fig. 11 shows the quantitative results of the amount of 7Crp accumulated. 2. Although the amount of 7Crp accumulated was smaller than when the 3 kGluB-1 promoter was used, the accumulation of 7Crp was observed in many strains. In addition, the transcript of the 7Crp gene in the ripening stage seeds of the TO generation transformants was examined by Northern analysis. The results are shown in the lower photograph of Fig. 11.
- the accumulation method of the present invention was carried out. Has been shown to be possible.
- T cell epipi T cell epipi
- the peptide was expressed in rice seeds.
- T-cell epitope peptides were expressed using the commonly used constitutive promoter, the maize shubiquitin promoter Dine ADP darcospirophorophylase (AGPase) promoter.
- AGPase maize shubiquitin promoter Dine ADP darcospirophorophylase
- GluB_l promoter showed the highest level of accumulation at 60 g / grain.
- the maize and ubiquitin promoter and AGPase promoter showing constitutive expression showed a maximum of 0.5 g and 10 pg per grain at a maximum.
- the accumulated amount increased about four times on average.
- the accumulation level was reduced to about 1/4 of that in the case where KDEL was added, and the cell wall was able to accumulate T cell peptide peptides, but was not suitable as an accumulation site.
- the accumulation in the protein granule II was as high as that when KDEL was added.
- Each mouse receives 1 xg of the sgia allergen Cryjl and 10 / zg of aram via the nose nine times every other day, and then feeds on rice powder containing 516 g of T-cell epitope peptide (7 crp) And fed for 31 days. Further, Cryjllg and alum were administered from the nose three times every other day. One week later, the mice were dissected, their spleens were removed, and T cell proliferation ability and IgE antibody levels were measured. The experiment was performed using OS.
- mice lymph node cells obtained by immunization are collected, in vi when stimulated with E peak 1 ⁇ one-flop of p Bok 211- 225 Cryj l and Cryj l in tro, 3 to lymph node cells whether the cell shows the proliferative response to these stimuli ( H) Evaluation was made using the thymidine incorporation value as an index.
- T-cell epitope-linked peptide having an effect of alleviating (treating) cedar pollinosis in rice seeds was successful.
- the results of the present invention enable production at lower cost than the synthesis using a T-cell epitope-linked peptide synthesis system using current chemical synthesis methods or Escherichia coli.
- T-cell epitope peptides accumulated in seeds are extremely stable (over 1 year) when stored at room temperature. It is also easy to control the amount of production. There is no need for special facilities, only a field. Furthermore, by ingesting orally through a daily diet, the cost and medical expenses required for administration by conventional subcutaneous injection and the like can be reduced, and the T-cell epitope-linked peptide can be administered at lower cost. by that leverage I Ne seed production systems with c these advantages is enabled, 7 allergic sputum such base peptide to mitigate vaccines and lifestyle diseases for patients, a medically useful components at lower cost It is also expected to create new businesses that produce and supply.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/554,308 US20070136896A1 (en) | 2003-04-24 | 2004-04-23 | Method of accumulating allergen-specific t cell antigen determinant in plant and plant having the antigen determinant accumulated therein |
CA002523459A CA2523459A1 (en) | 2003-04-24 | 2004-04-23 | Method of accumulating allergen-specific t cell antigen determinant in plant and plant having the antigen determinant accumulated therein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-120639 | 2003-04-24 | ||
JP2003120639A JP4512816B2 (ja) | 2003-04-24 | 2003-04-24 | アレルゲン特異的t細胞抗原決定基を植物へ集積させる方法、および該抗原決定基を集積させた植物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004094637A1 true WO2004094637A1 (ja) | 2004-11-04 |
Family
ID=33308144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/005938 WO2004094637A1 (ja) | 2003-04-24 | 2004-04-23 | アレルゲン特異的t細胞抗原決定基を植物へ集積させる方法、および該抗原決定基を集積させた植物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20070136896A1 (ja) |
JP (1) | JP4512816B2 (ja) |
CA (1) | CA2523459A1 (ja) |
WO (1) | WO2004094637A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005096806A1 (ja) * | 2004-04-09 | 2005-10-20 | Toudai Tlo, Ltd. | ワクチン遺伝子導入イネ |
WO2009048133A1 (ja) | 2007-10-12 | 2009-04-16 | National Institute Of Agrobiological Sciences | ダニ抗原米 |
US7595384B2 (en) | 2003-10-31 | 2009-09-29 | National Institute Of Agrobiological Sciences | Seed-specific gene promoter from the rice 10 KDa prolaminin gene and uses thereof |
CN109627306A (zh) * | 2019-01-25 | 2019-04-16 | 华中农业大学 | 水稻籽粒谷蛋白GluA2亚基的抗原表位、其抗体及应用 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006238821A (ja) * | 2005-03-04 | 2006-09-14 | National Agriculture & Food Research Organization | 機能性ペプチド含有ダイズ形質転換体およびその利用 |
US20090249513A1 (en) * | 2005-03-07 | 2009-10-01 | National University Corporation Nagoya University | Method for Expression and Accumulation of Peptide in Plant |
JP5158639B2 (ja) | 2008-04-11 | 2013-03-06 | 独立行政法人農業生物資源研究所 | 植物の内胚乳に特異的に発現する遺伝子および該遺伝子のプロモーター、並びにそれらの利用 |
JP5322051B2 (ja) * | 2008-08-05 | 2013-10-23 | 独立行政法人農業生物資源研究所 | 標的遺伝子を含む種子を判定する方法 |
CN102307995B (zh) * | 2008-11-28 | 2014-06-04 | 北兴化学工业株式会社 | 积累疫苗的转化的大豆植物及其用途 |
US8912145B2 (en) | 2008-11-28 | 2014-12-16 | Hokko Chemical Industry Co., Ltd. | Vaccine composition for prophylaxis and/or therapy of Alzheimer's disease |
US9260491B2 (en) | 2009-10-30 | 2016-02-16 | Nippon Paper Industries Co., Ltd. | Protein having immunogenicity of cedar pollen, polynucleotide encoding the protein, and use thereof |
CN101942477A (zh) * | 2010-08-04 | 2011-01-12 | 扬州大学 | 一种提高目标蛋白在转基因水稻胚乳中表达量的方法 |
JP2013040138A (ja) * | 2011-08-17 | 2013-02-28 | Univ Of Tsukuba | 活性化型リコンビナント花粉アレルゲンの作製方法 |
US9539300B2 (en) * | 2012-03-31 | 2017-01-10 | The Regents Of The University Of California | Modulating disease through genetic engineering of plants |
JP7256557B2 (ja) * | 2021-01-07 | 2023-04-12 | 国立研究開発法人農業・食品産業技術総合研究機構 | 遺伝子組換えイネ、並びに当該遺伝子組換えイネに由来するコメ、食品組成物、繁殖材料、種子および細胞 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5990384A (en) * | 1996-05-31 | 1999-11-23 | New Mexico State University | Co-expression of proteins |
IT1299565B1 (it) * | 1998-07-17 | 2000-03-16 | Plantechno S R L | Polinucleotide sintetico codificante per la lattoferrina umana, vettori, cellule e piante transgeniche che lo contengono. |
JP3422963B2 (ja) * | 1999-03-15 | 2003-07-07 | 株式会社林原生物化学研究所 | ペプチドおよびその用途 |
JP5263477B2 (ja) * | 2007-10-12 | 2013-08-14 | 独立行政法人農業生物資源研究所 | ダニ抗原米 |
-
2003
- 2003-04-24 JP JP2003120639A patent/JP4512816B2/ja not_active Expired - Lifetime
-
2004
- 2004-04-23 CA CA002523459A patent/CA2523459A1/en not_active Abandoned
- 2004-04-23 US US10/554,308 patent/US20070136896A1/en not_active Abandoned
- 2004-04-23 WO PCT/JP2004/005938 patent/WO2004094637A1/ja active Application Filing
Non-Patent Citations (4)
Title |
---|
SAITO S. ET AL.: "Sugi kafun allergen o hatsugen shita kumikae ine o mochiita men'eki ryoho", JAPANESE SOCIETY FOR IMMUNOLOGY SOKAI.GAKUJUTSU SOKAI KIROKU, vol. 32, 2002, pages 100, XP002984604 * |
TANAKA N.: "Sugi kafun chiryomai kyukyoku no "Taberudake" ryoho", NIKKEI BUSINESS, no. 1180, 24 February 2003 (2003-02-24), pages 120 - 122, XP002984605 * |
UTSUMI S. ET AL.: "Daizu tanpakushitsu o fukumu atarashii kome "Mamehikari"", KAGAKU TO SEIBUTSU, vol. 39, no. 3, 2001, pages 193 - 199, XP002984606 * |
XU H. ET AL.: "Combined use of regulatory elements within the cDNA to increase the production of a soluble mouse single-chain antibody, scFv, from Tobacco cell suspension cultures", PROTEIN EXPR. PURIF., vol. 24, no. 3, 2002, pages 384 - 394, XP004445147 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7595384B2 (en) | 2003-10-31 | 2009-09-29 | National Institute Of Agrobiological Sciences | Seed-specific gene promoter from the rice 10 KDa prolaminin gene and uses thereof |
US7619135B2 (en) | 2003-10-31 | 2009-11-17 | National Institute Of Agrobiological Sciences | Seed-specific promoter from the rice glutelin GluB-4 gene and uses thereof |
US7700835B2 (en) | 2003-10-31 | 2010-04-20 | National Institute Of Agrobiological Sciences | AGPase promoter from rice and uses thereof |
WO2005096806A1 (ja) * | 2004-04-09 | 2005-10-20 | Toudai Tlo, Ltd. | ワクチン遺伝子導入イネ |
WO2009048133A1 (ja) | 2007-10-12 | 2009-04-16 | National Institute Of Agrobiological Sciences | ダニ抗原米 |
JP2009095244A (ja) * | 2007-10-12 | 2009-05-07 | National Institute Of Agrobiological Sciences | ダニ抗原米 |
CN109627306A (zh) * | 2019-01-25 | 2019-04-16 | 华中农业大学 | 水稻籽粒谷蛋白GluA2亚基的抗原表位、其抗体及应用 |
CN109627306B (zh) * | 2019-01-25 | 2021-10-15 | 华中农业大学 | 水稻籽粒谷蛋白GluA2亚基的抗原表位、其抗体及应用 |
Also Published As
Publication number | Publication date |
---|---|
CA2523459A1 (en) | 2004-11-04 |
JP4512816B2 (ja) | 2010-07-28 |
US20070136896A1 (en) | 2007-06-14 |
JP2004321079A (ja) | 2004-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101065491B (zh) | 生产胶原的植物及其生成和使用方法 | |
WO2004094637A1 (ja) | アレルゲン特異的t細胞抗原決定基を植物へ集積させる方法、および該抗原決定基を集積させた植物 | |
CA2720268A1 (en) | Production of ospa for lyme disease control | |
CA2511221A1 (en) | Plant with reduced protein content in seed, method of constructing the same and method of using the same | |
JP2016214265A (ja) | スギ花粉の免疫原性を有するタンパク質、当該タンパク質をコードするポリヌクレオチド及びこれらの用途 | |
JP5709097B2 (ja) | ワクチンを蓄積する形質転換ダイズ植物およびその利用 | |
JP4847016B2 (ja) | 植物によって発現される組換えタンパク質による魚の免疫化 | |
US20090205068A1 (en) | Method for Producing Genetically Modified Plant Expressing Miraculin | |
JP2005204657A (ja) | タンニン含量が低減された植物体の生産方法およびこれを用いて得られる植物体、並びにその利用 | |
JP4769977B2 (ja) | ワクチン遺伝子導入イネ | |
JP4581098B2 (ja) | 植物でのペプチドの発現・集積方法 | |
AU2008311666B2 (en) | Mite antigenic rice | |
JP2006212019A (ja) | 植物を用いたユビキノン−10の製造方法 | |
JP7256557B2 (ja) | 遺伝子組換えイネ、並びに当該遺伝子組換えイネに由来するコメ、食品組成物、繁殖材料、種子および細胞 | |
Takaiwa | Transgenic rice seed as a nutriceutical delivery system. | |
JP7171079B2 (ja) | 遺伝子組換えイネ、並びに当該遺伝子組換えイネに由来するコメ、食品組成物、繁殖材料、種子および細胞 | |
US20220054628A1 (en) | Development of an edible vaccine | |
JP5105272B2 (ja) | アミロイドβペプチドをコードする遺伝子を含有したイネ | |
Wakasa et al. | Production of bioactive peptide in transgenic rice seed | |
Tamás | Molecular farming, using the cereal endosperm as bioreactor | |
KR20120079258A (ko) | 콜레라 독소 b 서브유닛과 돼지 유행성 설사 바이러스의 중화 항원결정기를 포함하는 재조합 유전자, 이를 발현하는 식물체 및 이의 용도 | |
TW201144438A (en) | Recombinant soybean storage protein for lowering triglyceride level in blood and method for preparing the same and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2523459 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007136896 Country of ref document: US Ref document number: 10554308 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10554308 Country of ref document: US |